PICASSO

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2024

Retrieved on: 
Tuesday, May 7, 2024
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, EAP, Cancer, MET, Congress, Safety, Haematopoietic system, Survival, Institut Gustave Roussy, Maat, Partnership, Trial of the century, Artificial intelligence, AP-HP, DSMB, ICI, IGR, PICASSO, Rated R, Patient, ARES, Doctor of Pharmacy, D28, INRAE, Lung, EBMT, ALS, AACR, NSCLC, Lung cancer, Pharmaceutical industry

MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to enhancing survival for patients with cancer, today provided a business update and highlights its key milestones for 2024.
  • Hervé Affagard, CEO and co-founder of MaaT Pharma said: “We're confidently advancing towards Phase 3 results for MaaT013, meeting milestones and delivering value for shareholders.
  • This study was not requested by regulatory authorities and does not impact cash projections as funding has already been secured.
  • The related costs for MaaT Pharma are limited to clinical product supply in line with previous cash projections.

MaaT Pharma indicates completion of Patient Recruitment for the Phase 2a Investigator-Sponsored Randomized Clinical Trial Evaluating MaaT013 in Combination with Immune Checkpoint Inhibitors in Metastatic Melanoma

Retrieved on: 
Tuesday, March 5, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, PICASSO, Week, Directorate, Neoplasm, Institut Gustave Roussy, PHRC, Ipilimumab, Nivolumab, ICI, National Cancer Institute, INRAE, Safety, MET, Patient, Survival, Cancer, Pharmaceutical industry

A total of 70 patients have been enrolled in 5 different centers in France in the randomized controlled Phase 2a PICASSO trial, which started in April 2022.

Key Points: 
  • A total of 70 patients have been enrolled in 5 different centers in France in the randomized controlled Phase 2a PICASSO trial, which started in April 2022.
  • The Company provided MaaT013 drug candidate and placebo and will contribute to the microbiome profiling of patients using its proprietary gutPrint® research engine.
  • The unblinding will be done at Week 27 (W27) to assess the primary endpoint which is safety.
  • Having reached this key recruitment milestone, the first publication will be submitted at the end of 2024 or in the first quarter of 2025.

MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results

Retrieved on: 
Thursday, November 9, 2023
Biotechnology, Pharmaceutical, Health, Bone marrow, Annual general meeting, Charcot disease, European Medicines Agency, Maat, ICI, HSCT, Randomized controlled trial, CFO, ASH, Artificial intelligence, EMA, Patient, DSMB, PICASSO, Medi-Cal Access Program, Aryl hydrocarbon receptor, Hematopoietic stem cell transplantation, Immunotherapy, EUR, Therapy, Symantec Endpoint Protection, ORR, Cancer, Survival, MET, SITC, ARES, CGMP, Development, Society, Pharmaceutical industry, Vaccine, ALS

We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.

Key Points: 
  • We are proud to achieve these milestones and we will continue to work on generating value for our shareholders,” stated Siân Crouzet, CFO of MaaT Pharma.
  • MaaT Pharma reported revenues from its compassionate access program of EUR 0.4 million for the quarter ended September 30, 2023 comparable with the third quarter of 2022.
  • 2 The Company would like to correct a clerical error that was present in its Q2 results press release of July 27, 2023.
  • The EUR 0.9 million figure was the difference in revenue between H1 2023 and H1 2022 (EUR 1.4 million vs. EUR 0.5 million).

MaaT Pharma Publishes its Half Year 2023 Results and Provides a Business Update

Retrieved on: 
Tuesday, September 26, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, EBMT, Partnership, CIMON, ASH, ICI, DSMB, Head, European Medicines Agency, Survival, Charcot disease, Clinical trial, Cancer, SITC, Immunotherapy, Maat, EMA, Development, ARES, Investigational New Drug, PICASSO, Patient, CGMP, Microbiome, Lifting, MET, European Society for Medical Oncology, APHP, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, IND, Food, Pharmaceutical industry, Nursing, Rare-earth element, Management, HSCT, Alexis de Tocqueville, ALS

Achieving these significant milestones reflects MaaT Pharma's unwavering commitment to progress and innovation.” stated Siân Crouzet, Chief Financial Officer of MaaT Pharma.

Key Points: 
  • Achieving these significant milestones reflects MaaT Pharma's unwavering commitment to progress and innovation.” stated Siân Crouzet, Chief Financial Officer of MaaT Pharma.
  • In June 2023 , MaaT Pharma also announced the appointment of Guilhaume Debroas as Head of Investor Relations.
  • As a post period event, in July 2023 , MaaT Pharma announced joining the Microbiome Therapeutics Innovation Group (MTIG).
  • The key unaudited financial results for the first half of 2023 are as follows:

MaaT Pharma Provides Second Quarter 2023 Business Update and Reports Financial Results

Retrieved on: 
Thursday, July 27, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, EBMT, IPO, EAP, CIMON, Failure, ICI, ASH, DSMB, Head, Charcot disease, Survival, Cancer, AGM, Research, American Society of Hematology, Maat, EMA, EUR, ARES, Science, Investigational New Drug, PICASSO, Patient, European, Microbiome, MET, Knowledge, European Society for Medical Oncology, APHP, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, IND, Society, ORR, Food, Pharmaceutical industry, Management, Lists of plant diseases, ALS

"As a leading microbiome company in oncology, we are proud of the progress made in the second quarter of 2023.

Key Points: 
  • "As a leading microbiome company in oncology, we are proud of the progress made in the second quarter of 2023.
  • In June 2023 , MaaT Pharma announced the appointment of Guilhaume Debroas as Head of Investor Relations.
  • As a post period event, in July 2023 , MaaT Pharma announced having joined the Microbiome Therapeutics Innovation Group (MTIG).
  • MaaT Pharma reported revenues2 from its compassionate access program of EUR 0.7 million for the quarter ended June 30, 2023, comparable with EUR 0.7 million for the first quarter of 2023.

MaaT Pharma Reports Cash and Revenues for Third Quarter 2022

Retrieved on: 
Tuesday, November 8, 2022
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Kepler, Euronext Paris, Achievement, ANSM, Company, Digital, Society, IHMC, Maat, ARES, Agence nationale de sécurité du médicament et des produits de santé, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Salvage therapy, EUR, Drug design, IPO, Congress, EST, CGMP, Graft-versus-host disease, Survival, Forward-looking statement, Conference, Special access program, LSX, Annual general meeting, PICASSO, FDA, Biomarker, CIMON, Communication, Drug, ASH, R, Safety, CEO, Food, Showcase, EAP, Patient, Cancer, MET, Lymphatic system, CIC, UCSD Student-Run Free Clinic Project, Acute myeloid leukemia, International, Pharmaceutical industry, Film, Fine chemical

MaaT Pharma (EURONEXT: MAAT the Company), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today reported its cash position as of September 30, 2022, and its revenues for the third quarter of 2022.

Key Points: 
  • MaaT Pharma (EURONEXT: MAAT the Company), a French clinical-stage biotech and a pioneer in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today reported its cash position as of September 30, 2022, and its revenues for the third quarter of 2022.
  • The net increase in cash over the third quarter of 2022 was EUR 1.9 million.
  • November 15-17, 2022 13th Annual Jefferies London Healthcare Conference London, UK: Sin Crouzet, Chief Financial Officer of MaaT Pharma and Dr. Carole Schwintner, Chief Technology Officer of MaaT Pharma will attend the conference.
  • November 29, 2022 Investir day Paris, France: Sin Crouzet, Chief Financial Officer of MaaT Pharma and Dr. Savita Bernal, Chief Business Officer of MaaT Pharma will attend the investor event.

MaaT Pharma Publishes its Half Year Results and Provides a Business Overview

Retrieved on: 
Thursday, September 29, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ICI, Therapy, Global, Safety, CIC, FDA, Food, Biomarker, PICASSO, CGMP, Association, Maat, Company, Growth, Partnership, Achievement, Forward-looking statement, Patient, Clinical trial, Market Access Program, Hematopoietic stem cell transplantation, BNP Paribas, Ecosystem, ARES, Lymphatic system, Research, Graft-versus-host disease, R, Operating cost, Communication, CIMON, CERA, Euronext Paris, AP-HP, Pharmaceutical industry, Dietary supplement, Cryptocurrency, Fine chemical, Caisse, Euronext

Operating loss amounted to 7.4 million compared with 4.0 million in the first half of 2021, an increase of 3.4 million.

Key Points: 
  • Operating loss amounted to 7.4 million compared with 4.0 million in the first half of 2021, an increase of 3.4 million.
  • The trial is sponsored by AP-HP with MaaT Pharma supplying drug candidates and performing the microbiome profiling of patients using its proprietary gutPrint platform.
  • A second down payment was made to Skyepharma by the Company in the first half of 2022.
  • MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology.